January 2024 in “Circulation” This commentary explores the role of PCSK9 as a target for drug development, underscoring that individuals with PCSK9 loss-of-function mutations experience significantly lowered LDL cholesterol levels and reduced coronary events, suggesting that full inactivation of PCSK9 is effective and safe.
This study introduced Cadd4, a peptide-based degrader developed using computer-aided drug design, which effectively reduced PCSK9 levels and increased LDL receptor expression, resulting in decreased plasma cholesterol and LDL-C levels in hypercholesterolemic mice, without liver toxicity.
September 1992 in “Journal of Dermatological Science” 13 citations
,
February 2024 in “Clinical Epigenetics” In this study, the authors review how epigenetic regulation influences the role of iPSC-derived neural stem/progenitor cells in spinal cord injury therapy, highlighting challenges in the cells' generation, differentiation, and transplantation, and the effect of therapeutic tools on these processes.
16 citations
,
July 2020 in “Health and Quality of Life Outcomes” This study found that health-related quality of life was significantly lower in women with polycystic ovary syndrome, especially those with the anovulatory phenotype, compared to non-PCOS controls attending a tertiary hospital.